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ABSTRACT
Dengue is a potentially deadly disease with no effective drug. An in silico molecular docking was performed using Autodock 
4.2.6 to investigate the molecular interactions between protease inhibitors, comprising antibiotic derivatives namely 
doxycycline (3), rolitetracycline (5) and a non-steroidal anti-inflammatory drug (NSAID), meclofenamic acid (4), against 
the NS2B-NS3 protease from dengue virus-2 (DENV-2). The non-competitive inhibitor (3) showed lower binding energy 
(-5.15 kcal/mol) than the predicted competitive inhibitors 4 and 5 (-3.64 and -3.21 kcal/mol, respectively). Structural 
analyses showed compound 3 that bound to a specific allosteric site, interacted with Lys74, a significant amino acid 
residue bonded to one of the catalytic triad, Asp75. Compounds 4 and 5 showed direct binding with two of the catalytic 
triad, His51 and Ser135, hence, predicted to be competitive inhibitors.
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ABSTRAK
Denggi adalah sejenis penyakit yang boleh membawa maut dan sehingga kini tiada sebarang ubat untuk merawat penyakit 
tersebut. Mengedok molekul secara in silico menggunakan Autodock 4.2.6 telah dijalankan untuk mengkaji interaksi 
molekul antara perencat protease yang terdiri daripada derivatif antibiotik iaitu doxycycline (3) dan rolitetracycline 
(5) dan dadah anti-radang bukan steroid (NSAID), asid meklofenamik (4), terhadap NS2B-NS3 daripada virus denggi-2 
(DENV-2). Perencat tidak-kompetitif (3) menunjukkan tenaga ikatan yang lebih rendah (-5.15 kcal/mol) berbanding 
sebatian 4 dan 5 (masing-masing -3.64 dan -3.21 kcal/mol). Analisis struktur menunjukkan sebatian 3 yang terikat pada 
kawasan alosterik, berinteraksi dengan Lys74, iaitu residu asid amino yang terikat dengan salah satu daripada residu 
triad pemangkinan, Asp75. Sebatian 4 dan 5 pula menunjukkan ikatan langsung dengan dua triad pemangkinan iaitu 
His51 dan Ser135, justeru diramalkan sebagai perencat kompetitif. 
Kata kunci: Mengedok; NS2B-NS3 protease; perencat; virus denggi-2
INTRODUCTION
Dengue is an infection caused by the dengue virus (DENV) 
of the Flaviviridae family (Sukupolvi-Petty et al. 2007) 
and is transmitted by infected female mosquitoes (Bhatt 
et al. 2013; Kyle & Harris 2006). Dengue virus has four 
serotypes (DENV-1 to -4) that genetically share ~65% 
similarities (Mustafa et al. 2015). Although the distinctive 
DENV-5 (transmitted through non-human primates) has 
been recently discovered (Normile 2013), DENV-2 is 
still classified as the world’s most epidemiologically 
and geographically prevalent arboviral disease causing 
pathogen (Panhuis et al. 2010). Dengue is transmitted in 
more than 100 tropical and subtropical countries, with 
40% of the populations at risk (Heilman et al. 2014). DENV 
infection causes an acute dengue fever (DF), severe dengue 
hemorrhagic fever (DHF) and dengue shock syndrome 
(DSS) (Kadir et al. 2013; Sun & Kochel 2013). Therapeutic 
treatments against dengue infections are currently being 
developed (Amorim et al. 2014; Bhatt et al. 2013; Byrd 
et al. 2013; Heilman et al. 2014). But until now, there are 
no licensed antivirals available and prevention has been 
limited to vector control measures and disease surveillance 
(Ong 2016; Wan-Norafikah et al. 2012).
 DENV is a single-stranded positive-sense RNA genome 
of ~11 kb that encodes a single open reading frame 
(5′-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-
NS5-3′) with three structural and seven non-structural 
(NS) proteins (Leung et al. 2001). The N-terminal of 180 
residues of NS3 is a trypsine-like serine protease (Falgout 
et al. 1991), which when combined with its co-factor 
(47 amino acid hydrophilic region of NS2B), is able to 
cleave the viral polyprotein in cis and trans (Chiu et al. 
2007). Disruption of NS2B-NS3 protease inhibits the viral 
replication (Chen et al. 2014; Wang et al. 2002). This poses 
NS2B-NS3 protease of DENV-2 as a promising target for 
antiviral drug design (Tomlinson et al. 2009).
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 Several antibiotics had shown to inhibit dengue viruses 
(Kaptein et al. 2010; Low et al. 2011; Rothan et al. 2014a; 
Zhang et al. 2009). Antibiotics such as doxycycline (3) and 
rolitetracycline (5) showed significant inhibitory activity 
against NS2B-NS3 protease of DENV-2 (Rothan et al. 
2014b, 2013). Furthermore, previous finding had shown 
that non-steroidal anti-inflammatory drug (NSAID), such as 
meclofenamic acid (4), was not only used to treat symptoms 
of dengue infections (Kumar et al. 2015) but also to inhibit 
the NS2B-NS3 protease (Rothan et al. 2013). Keeping this 
in view, in silico molecular docking was performed using 
Autodock 4.2.6 software to study the interactions of these 
small molecule compounds (also termed as ligands) with 
NS2B-NS3 protease of DENV-2. The structural model of the 
protease, namely DH-1 (Heh et al. 2013), was used as the 
target protein. Pinostrobin (1) and 4-hydroxypanduratin A 
(2) were utilized as standard ligands, each representing the 
non-competitive and competitive inhibitors of NS2B-NS3 
protease of DENV-2, respectively (Frimayanti et al. 2011; 
Heh et al. 2013; Kiat et al. 2006; Othman et al. 2008). 
Therefore, this study aimed to investigate the binding 
interactions and search for the best orientation of ligand-
protease complex with the lowest binding energy involving 
the selected antibiotics and NSAID.
MATERIALS AND METHODS
An Intel Core 2 Duo E6850 3.00 GHz microprocessor, 
generated with a random access memory of 8 GB and an 
Ubuntu 10.04 Linux operating system were utilized to 
prepare the docking files, run the docking jobs and analyse 
the output.
PROTEIN STRUCTURE
Coordinate file for the 3D homology model of NS2B-NS3 
protease of DENV-2, namely DH-1, was retrieved from Heh 
et al. (2013). This model had been previously minimized, 
water molecules were removed, non-polar hydrogen atoms 
were merged, Kollman charges were assigned and the 
solvation parameters were added.
OPTIMIZATION OF LIGAND STRUCTURES
The ligands’ 3D structures were downloaded from the 
PubChem webpage (http://www.ncbi.nlm.nih.gov/
pccompound). The ligands’ structural energy was stabilized 
by minimization using the Hyperchem Pro 6.0 software 
system, employing the PM3 semiempirical method, 
geometrical optimisation using steepest descent and the 
operational termination at a maximum setting of 500 
cycles or 0.01 kcal/(Å mol) rms gradient. Figure 1 shows 
the structures of the standard and target ligands.
PREPARATION OF INPUT FILES FOR BLIND DOCKING
Input files for rigid protein and flexible ligands were 
prepared using the AutoDock Tools 1.5.6 software (http://
www.mybiosoftware.com/autodock-4-2-3-autodocktools-
1-5-6-suite-automated-docking-tools.html). Polar and non-
polar hydrogen atoms were individually added and merged 
to the protein structure. Kollman charges and solvation 
parameters were determined by default. Gasteiger charges 
were added to the minimized ligand structures, and all 
bonds were made rotatable and flexible by allowing the 
detection of root torsion.
 Grid maps with grid spacing of 0.41 Å in the x, y and 
z-dimensions of 126 × 126 × 126 points were set to cover 
the entire protein. The Lamarckian Genetic Algorithm 
(LGA) was used to search for the lowest binding energy by 
implementing local minimization of the genetic algorithm, 
to enable modification of the gene population (Atilgan 
& Hu 2011). LGA parameters were set as follows: 100 
search (docking) runs; population size of 150; 25,000,000 
FIGURE 1. Molecular structures of ligands used in this study. Standard ligands were pinostrobin (1) 
(non-competitive inhibitor) and 4-hydroxypanduratin A (2) (competitive inhibitor). Target ligands 
were doxycycline (3), meclofenamic acid (4) and rolitetracycline (5)
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of energy evaluations; 27,000 numbers of generations; 
mutation rate of 0.02 and crossover rate of 0.8. Docking 
calculation was performed in the AutoDock 4.2.6 software. 
The output was clustered based on the root-mean-square 
deviation (RMSD) tolerance of 2.0 Å. 
ANALYSIS OF DOCKED RESULTS
The best docked ligand models were selected according 
to the lowest binding energy that comprised the largest 
conformational cluster in each binding. Two and three-
dimensional conformational structures of the ligand-
protein complexes were visualized using the Discovery 
Studio Visualizer 4.5 (http://accelrys.com/products/
collaborative-science/biovia-discovery-studio/) to 
investigate the binding modes. Hydrophobic interactions 
were evaluated using the Ligplot program (http://www.
ebi.ac.uk/thorntonsrv/software/LigPlus/download.html). 
RESULTS AND DISCUSSION
In this study, in silico investigation showed that medicinal 
drugs could have potentials as DENV-2 inhibitors. 
Computational docking studies highlighted that these 
drugs could bind tightly to the active and allosteric sites 
of DENV-2 NS2B-NS3 protease. In silico molecular 
docking is a good tool to predict and match the desired 
binding site, understanding possible conformation of the 
compounds and further clarifies the binding interactions 
in the binding pocket (Grinter & Zou 2014). Structural 
homology model built by Heh et al. (2013), namely DH-
1, was utilized instead of its crystal structure, due to the 
missing loop between Ile76 and Ser85 of the NS2B region 
(Erbel et al. 2006). DH-1 was previously modelled based 
on the crystal structure of dengue (PDBid: 2FOM) and West 
Nile (2FP7) viruses with 89% of its residues were located 
in the most favored region of the Ramachandran plot (Heh 
et al. 2013). By using 2FP7 as the template, Thr77, Ile78, 
Ser79, Glu80 Asp81, Gly82, Ser83 and Met84 were added 
to merge the existing gap. Blind docking was applied to 
the current work using the complete structural model of 
the target protein (DH-1). The docking methodology was 
validated using the standard ligands, pinostrobin (1) and 
4-hydroxypanduratin A (2), each representing the non-
competitive and competitive inhibitors, respectively.
 Previous in vitro studies had highlighted the inhibitory 
potentials for compounds 3, 4 and 5 (Table 1), with 
compound 3 reported to be non-competitive (Rothan et 
al. 2014b, 2013). Therefore, the current docking study 
was conducted not only to determine the ligand poses in 
the binding sites and the interactions involved, but also 
to determine the sites to which compounds 4 and 5 were 
bound and to further validate the inhibitory characteristic 
of compound 3. The target protein (DH-1) was assigned to 
be rigid. Meanwhile, the ligands were made flexible by 
retaining the structural rotatable bonds (Table 1), which 
would increase the number of ligands’ conformations 
and the probability to bind to the potential binding site 
(Atkovska et al. 2014; Hetényi & Spoel 2006). Blind 
docking was used to maneuver the ligands over the entire 
surface of the protein and their tendency to bind to the 
allosteric and/or active sites were observed. Although 
prediction of docked complex using blind docking is 
difficult, it allows the ligand to bind the actual binding 
site rather than to the nonspecific and/or energetically 
unfavorable sites inside the protein (Hetényi & Spoel 2006). 
SCORING FUNCTION
The scoring function for the docking run is presented as 
the binding energy, Ebind (Table 1). The non-competitive 
inhibitors (1 and 3) are top in the ranking (low binding 
energy values, Ebind) followed by the competitive 
compounds (2, 4 and 5). Compound 3 shows the lowest 
Ebind value (-5.15 kcal/mol) indicating the highest binding 
affinity (Datar & Jadhav 2015) towards NS2B-NS3 
TABLE 1. Relationship between the predicted binding energies obtained from docking runs and the experimental 
inhibitory activities reported from previous studies
 Docking  Experimental
ID No. of 
atoms
No. of
 rotatable bonds
Ebind a
(kcal/mol)
IC50 b
(μg/ml)
Ki c
(μM)
% Inhibition 6
 25 μM 100 μM
1 34 3 -5.33 90.48 1 348 ±70 2
345 ± 70 3
NA
NA
2 57 8 -4.45 40 3 21 3 NA NA
3 56 8 -5.15 52.3 ± 6.2 (at 37°C) 4
26.7 ± 6.2 (at 40°C) 4
55.6 6
55.6 ± 5.7 5 35.6 ± 3.2 53.8 ± 2.8
4 30 4 -3.64 NA NA 19.4 ± 2.2 43.0 ± 1.4
5 71 10 -3.21 67.1 6 NA 32.8 ± 2.6 38.9 ± 2.9
a Lowest binding energy. b Half maximal inhibitory concentration. c Inhibition constant.
1 Othman et al. (2008); 2 Heh et al. (2013); 3 Kiat et al. (2006); 4 Rothan et al. (2014b); 5 Rothan et al. (2013); 6 Yang et al. (2007).
1 = Pinostrobin; 2 = 4-hydroxypanduratin A; 3 = Doxycycline; 4 = Meclofenamic acid; 5 = Rolitetracycline. NA = Not available
1868 
protease of DENV-2 compared to compounds 4 and 5 (-3.64 
and -3.21 kcal/mol, respectively). 
 In general, the trend for the computed Ebind values 
did not correlate with the trend of the experimentally 
determined IC50 and Ki values obtained from previous 
studies (Table 1). To explain the experimental observation, 
in depth analyses of the binding interactions was 
performed. 
NON-COMPETITIVE AND COMPETITIVE INHIBITORS
Figure 2 shows the top ranking docked poses of the ligands 
and standards. The standard (compound 1) and compound 
3 bound to the same allosteric site, which is proximal to 
the protease active site. This result correlates with findings 
reported by Rothan et al. (2013), which showed compound 
3 as a non-competitive inhibitor of DENV-2 NS2B-NS3 
protease. On the other hand, the inhibitory characteristic 
for compounds 4 and 5 was not described (Rothan et al. 
2013). In the current docking study, both compounds were 
predicted to be competitive inhibitors since they docked 
to the active site of the protease. As shown in Figure 2, 
compounds 4 and 5 bound to the same (active) site as with 
the standard (compound 2; competitive inhibitor) located 
close to His51 and Ser135.
 Tables 2 and 3 list the amino acid residues in the 
binding site that interact with the ligands. As can be seen, 
some key residues interacted with both the standard and 
tested ligands, thus underlining the mode of inhibition of 
these ligands. For the non-competitive inhibition, out of 
the twenty-two amino acid residues in the binding site 
that are involved in the interactions with the ligands, five 
residues were involved in binding to compounds 1 and 3, 
namely Lys74, Ala164, Ile165, Ala166, and Asn167. These 
residues are located at a specific region in the allosteric 
pocket (proximal to the catalytic triad), thus confirming the 
non-competitive inhibitory characteristic of compound 3. 
Additionally, Lys74 is a crucial residue in the allosteric site 
(Heh et al. 2013; Othman et al. 2008) and in this study, it 
is involved in the hydrophobic interaction with both the 
standard (1) and target (3) ligands (Table 3 and Figure 4).
 Meanwhile, out of the sixteen residues that interacted 
with the standard (2) and compounds 4 and 5 ligands, 
ten residues (Phe130, Thr134, Tyr150, Gly151, Asn152, 
Gly153, Val155, Tyr161, and two of the catalytic triad, 
His51 and Ser135), interact with all the three ligands, 
underlining the competitive inhibitory characteristics of 
compounds 4 and 5.
BINDING INTERACTIONS
Figure 3 shows the poses and the non-covalent interactions 
involved between the ligands and the protease-binding 
site. Hydrogen bond donors (HBD) and acceptors (HBA) 
FIGURE 2. Three-dimensional structure highlighting the best binding mode of ligands (sticks) in NS2B-NS3 
protease of DENV-2 (ribbons). NS2B is highlighted in moss green while NS3 protease in ribbons with elementary 
color. Compounds 1 (orange) and 2 (white) are the standard ligands, while compounds 3, 4 and 5 are displayed 
in green, pink and yellow, respectively. Residues His51, Asp75 and Ser135 (elementary-colored sticks) are the 
catalytic triad. The image was generated using the Discovery Studio Visualizer 4.5 2
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FIGURE 2. Three-dimensional structure highlighting the best binding mode of ligands (sticks) in NS2B-NS3 
protease of DENV-2 (ribbons). NS2B is highlighted in moss green while NS3 protease in ribbons with elementary 
color. Compounds 1 (orange) and 2 (white) are the standard ligands, while compounds 3, 4 and 5 are displayed 
in green, pink and yellow, respectively. Residues His51, Asp75 and Ser135 (elementary-colored sticks) are the 
catalytic triad. The image was generated using the Discovery Studio Visualizer 4.5 2
TABLE 2.  Residues involved in the H-bonding, pi-H bonding and dipole-dipole interactions in the ligand-protease 
complex, as determined using Discovery Studio 4.5 Visualizer
ID  H-bond  Pi-H-bond Dipole-dipole
 Donors  Acceptors Distances
Atoms F. groups Atoms F.groups (Å)
1 B:Asn152:HD21 
B:Asn167:HN 
H31
-NH
-NH
-OH
O4
O3
B:Asn167:O
-C-O-C-
-OH
-C=O
 1.93527
1.83825
1.90466
 NA  C20 – B:Asn152:O
2 B:Gly153: HN 
H56 
H57 
-NH
-OH
-OH
O3 
B:Asn152:OD1
A:Met84:O
-OH
-C=O
-C=O
1.85400
1.70581
2.10307
NA A:Ser83:CB – Ob1
3 B:Asn167:HD22 
B:Asn167:HD22 
H54
H50 
H42 
H51 
H56 
-NH
-NH
-NH
-OH
-OH
-OH
-OH
O3
O5
B:Trp89:O
B:Thr122:O
B:Thr122:O
B:Ile165:O
B:Ile165:O
-C=O
-OH
-C=O
-C=O
-C=O
-C=O
-C=O
1.89173
2.63800
2.38811
2.06387
1.64877
1.90640
2.35336
B:Asn167:HN – b C28 – B:Glu88:OE1
4 B:His51:HE2 
B:His51:HE2 
H30
-NH
-NH
-OH* 
O4
O3
B: Gly151:O
-C=O*
-OH*
-C=O
2.11584
2.21816
2.31655
NA NA
5 H47 
H57 
H57 
H71 
B:Gly153:HN
-OH
-OH
-OH
-OH
-NH
B:Phe130:O
B:Gly151:O
B:Tyr161:OH
B:Tyr161:OH
O7
-C=O
-C=O
-OH
-OH
-OH
1.78001
2.24901
2.18301
2.00355
2.72705
NA B:Asn152:CA – O7
* Carbonyl (-C=O) and hydroxyl (-OH) groups from the same carboxyl (-COOH) functional group. 
1 = Pinostrobin; 2 = 4-hydroxypanduratin A; 3 = Doxycycline; 4 = Meclofenamic acid; 5 = Rolitetracycline. F. groups = Functional groups; – = Interacts with. b1 = Benzene 
1; A = NS2B chain in the NS2B-NS3 protease; B = NS3 protease chain in the NS2B-NS3 protease; NA = Not available. For H-bond donors and acceptors, the functional 
group from where the atom derived is mentioned; and the atoms that are displayed as individuals are indicating contributors from the ligand.
and the length of H-bonds are further clarified in Table 
2. The (non-competitive) compound 3 involved the most 
number of H-bonds with Asn167, Trp89, Thr122 and Ile165 
in the allosteric site. While the (competitive) compound 4 
exhibited H-bonding interactions with one of the catalytic 
triad (His51) and Gly151, compound 5 formed H-bonds 
with Gly151, in addition to Phe130, Gly153 and Tyr161. 
There were seven H-bonds in compound 3 that involved 
the amino and hydroxyl groups (HBD) (Table 2). Other non-
covalent interactions were the pi-H-bonding with Asn167, 
carbon-oxygen dipole-dipole interaction with Glu88 (Table 
2) and van der Waals interactions with Glu91, Thr120, 
Gly124, Ala164, Ala166 (Table 3). Pi-H-bond is a point to 
pi-plane interactions that allows more conformations and 
larger energy range (2 to 7 kcal/mol) than the conventional 
H-bond and electrostatic interactions (Du et al. 2013). The 
phenolic ring of compound 3 formed a pi-H-bond with the 
hydrogen from the amino group of Asn167. On the other 
hand, no pi-H-bond was observed involving compounds 
4 and 5. This suggested why compound 3 had the lowest 
binding energy among the three target ligands.
 Compound 5, which was predicted to be competitive 
inhibitor, involved five H-bonding while compound 
4 (competitive inhibitor) showed only three (Table 2 
and Figure 3). However, compound 4 showed a higher 
scoring function (lower Ebind) which could be attributable 
to the two H-bonds that was formed between its carboxyl 
oxygen atom with the hydrogen atom of the amino group 
from one of the catalytic triad, His51 (Duax et al. 2005) 
(Table 2 and Figure 3, left). The carboxyl group had a 
greater number of dipoles contributed from the strongly 
polarized carbonyl and hydroxyl functional groups, which 
added to the compound’s strong binding affinity (Lifson 
et al. 1979). On the contrary, H-bonding with compound 
5 involved solely the individual carbonyl and hydroxyl 
groups, respectively (Table 2). 
 From Table 3, van der Waals interaction was also 
observed in both compounds 4 and 5, involving Ser135 
(one of the catalytic triad) and other residues namely 
Thr134, Tyr150 and Val154. Individually, other residues 
involved in van der Waals interaction with compound 4 
were Phe130, Ser131, Pro132, Asn152 and Gly153 and 
Asp129 with compound 5. Pi interaction such as alkyl-
pi was observed between compound 4 with Val155 and 
Tyr161. Meanwhile, two benzene rings in compound 4 
appeared to have a T-shaped pi-pi stacking interaction 
with Tyr161. For compound 5, both cation-pi and pi-pi 
stacking interactions were engaged with His51 (from the 
catalytic triad), which were also clearly observable in the 
3D structure (Figure 3, left).
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 A 2D visual inspection of hydrophobic interaction is 
depicted in Figure 4. As previously mentioned, the non-
competitive inhibitor (3) exhibited hydrophobic interaction 
with Lys74, a key residue in the protease allosteric site 
(Othman et al. 2008) and with Glu88, Ile123, Ala164 and 
Ala166. Likewise, the standard ligand (1) also exhibited 
hydrophobic interaction with Lys74, Ala164 and Ala166, 
and additionally with Asp71, Lys73, Ile78 and Met84. In 
the case of the competitive ligands 4 and 5, both exhibited 
hydrophobic interactions with one of the catalytic triad, 
Ser135 and with Gly153, Val154 and Val155. Additionally, 
compound 4 also interacted with Phe130, Ser131, Thr134, 
Tyr150 and Tyr161, while compound 5 interacted with 
Pro132, Asn152 and a residue from the catalytic triad, 
His51. Among these residues, Phe130, Tyr150, Val155, 
Tyr161 and His51 (a catalytic triad) showed hydrophobic 
interactions with the standard competitive inhibitor (2). 
Meanwhile, Asp75, Ser83, Asp129 and Gly151 were 
additional residues found in the standard (2) but not in 
compounds 4 and 5. 
BINDING POCKET AND ELECTROSTATIC 
POTENTIAL SURFACE (EPS)
The binding pocket of NS2B-NS3 protease to where all 
compounds 3, 4 and 5 were bound, is divided into two; 
the left and right regions (Figure 5). For compound 3, the 
cyclohexenone scaffold (with the amide and tertiary amine 
functional groups) and a tetrahydroquinone scaffold are 
resided in the left cleft, while the right cleft was filled with 
the cyclohexanol and phenolic scaffolds. Both compounds 
TABLE 3. Residues involved in pi-effects, van der Waals forces and hydrophobic interactions
ID Alkyl-pi Sigma-pi Cation-pi Pi-pi stacking T-shaped pi-pi van der Waals Hydrophobic
1 B:Lys73 – b1
B:Lys74 – b1
B:Lys74 – b2
A:Ile78 – b1
B:Ala164 – b1
B:Ala166 – b2
NA NA NA NA B:Ile165
B:Asp71
A:Met84
B:Asp71
B:Lys73
B:Lys74
A:Ile78
A:Met84
B:Ala164
B:Ala166
2 B:His51 – chy 
B:Tyr150 – C14
B:Tyr161 – C26
C25 – B:Tyr161 NA NA B:His51 – b2 B:Asp75
B:Asp129
B:Phe130
B:Thr134
B:Ser135
B:Gly151
B:Gly153
B:Val155
B:His51 
B:Asp75
A:Ser83
B:Asp129
B:Phe130
B:Tyr150
B:Gly151
B:Val155
B:Tyr161
3 NA NA NA NA NA B:Glu91
B:Thr120
B:Gly124
B:Ala164
B:Ala166
B:Lys74 
B:Glu88
B:Ile123
B:Ala164
B:Ala166
4 B:Val155 – C16
B:Tyr161 – Cl1
B:Tyr161 – C16
NA NA NA B:Tyr161 – b1
B:Tyr161 – b2
B:Phe130
B:Ser131
B:Pro132
B:Thr134
B:Ser135
B:Tyr150
B:Asn152
B:Gly153
B:Val154
B:Phe130
B:Ser131
B:Thr134
B:Ser135
B:Tyr150
B:Gly153
B:Val154
B:Val155
B:Tyr161
5 NA NA B:His51:NE2 – b B:His51 – b NA B:Asp129
B:Thr134
B:Ser135
B:Tyr150
B:Val154
B:His51
B:Pro132
B:Ser135
B:Asn152
B:Gly153
B:Val154
B:Val155
1 = Pinostrobin; 2 = 4 hydroxypanduratin A; 3 = Doxycycline; 4 = Meclofenamic acid; 5 = Rolitetracycline; – = Interacts with; b = Benzene; b1 = Benzene 1; b2 = Benzene 
2; chy = Cyclohexenyl scaffold; cho = Cyclohexanone; chol = Cyclohexenol scaffold; py = Pyrrolidine; A = NS2B chain in the NS2B-NS3 protease; B = NS3pro chain in 
the NS2B-NS3 protease; NA = Not available. Atoms stated individually are indicating contributors from the ligand
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FIGURE 3. The 3D (left) and 2D (right) structural views of ligand-binding site interactions. The 3D structures display H-bond 
interactions (green dashed lines) between compounds 3, 4 and 5 (sticks) and the binding site (wire frames). A clear observation 
of cation-pi (orange line) and pi-pi stacking (pink dashed line) can be observed only in compound 5. Main residues from both 
the allosteric site, Lys74 (pink) and the catalytic triad, His51 and Ser135 (orange) are observed. Simplified visualization is 
illustrated in 2D, which displays the H-bonding (dark green circles associated with the green dashed lines); van der Waals 
forces (medium light green circles); carbon-oxygen dipole-dipole interaction (light green circles with dashed lines); alkyl-pi 
interactions (light pink circles with dashed lines); T-shaped pi-pi stacking and (parallel) pi-pi stacking (both indicated with 
dark pink circles); cation-pi interaction (orange circle). The blue halo surrounding the interacting residues represents the 
solvent accessible surface that is proportional to its diameter. Images were generated using Discovery Studio Visualizer 4.5
4 and 5 were inclined towards the left region of the binding 
pocket, leaving a more spacious area to the right region 
of the pocket (Figure 5, top). The dichlorotoluene ring 
in compound 4 is observed to be occupying the centre of 
the binding site, while the benzoic acid moiety resided 
in the top region of the binding site (Figure 5, top). 
Comparatively, compound 5 occupied the whole binding 
pocket with both the terminal pyrrolidine and phenolic rings 
were bent towards the left side of the cleft (Figure 5, top). 
Meanwhile, the right cleft was filled with most part of the 
4-methylcyclohexen-1,4-diol moiety, the cyclohexanone 
and cyclohexenone scaffolds with the tertiary amine and 
hydroxyl functional groups. Additionally, the amide group 
was found situated in the middle of the binding clefts.
 The shape complementary of a drug with its binding 
pocket is important in determining the affinity and the 
specificity of the drug (Bespamyatnikh et al. 2004). The 
best shape complementary could be seen with compound 3, 
where the binding pocket was narrow and deep, indicating 
a stronger ligand affinity (Fukunishi & Nakamura 2011), 
as compared to the more shallow and broader pocket 
enclosing compounds 4 and 5. Looking at the connolly 
surface representation of the binding sites the affinity of 
compound 3 was further enhanced by the large distribution 
of the negative electrostatic potential surface (EPS) (dark 
red) (Atkins & Paula 2014) on the left side of the binding 
pocket, which attracted the tertiary amine functional group 
(the upper region) and the amide side chain (the left region) 
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(Figure 5, left and top). On the contrary, for compounds 
4 and 5, it could be observed that there was a smaller 
area of negative EPS towards the right side of the binding 
pocket. As a result, the dichlorotoluene ring in compound 
4 could be repelled and bent towards the left side of the 
cleft (Figure 5, all views). But in the case of compound 5, 
this negative EPS could have attracted the tertiary amine 
functional group (Figure 5, right and top). Generally, 
compounds 4 and 5 bound to the same pocket, indicating 
similar core of EPS that could possibly explain their similar 
values for Ebind (Kellenberger et al. 2008). However, as 
discussed, each compound had its own favourable binding 
interactions, which when combined with the binding pocket 
shape complementary, may lead to the different levels of 
inhibition activity.
CONCLUSION
From the in silico docking study, doxycycline (3) was 
shown to bind to an allosteric site, underlining its non-
competitive mode of inhibition of the NS2B-NS3 protease 
of DENV-2. One of the interactions involved Lys74, a 
key residue for non-competitive inhibitors to interact 
with. Meclofenamic acid (4) and rolitetracycline (5) 
were predicted as competitive inhibitors based on their 
interactions with His51 and Ser135, two amino acid 
residues which comprised the protease catalytic triad. 
Higher binding affinity for compound 3 was observed to 
match with its deep binding pocket, while compounds 
with lower binding affinities (4 and 5) showed a shallow 
binding pocket. The presence of a pi-H-bond with Asn167, 
together with the deep binding pocket, could explain 
for the high binding affinity in compound 3. The lower 
binding affinity observed with compounds 4 and 5 could be 
attributable to their binding to the shallow binding pocket. 
Both compounds interacted with His51, but compound 4 
involved H-bonding with this residue, which could explain 
its higher binding affinity compared to compound 5. In 
conclusion, this study has provided further understanding 
on the binding mode and interactions of these inhibitors 
with DENV-2 protease, which may be useful in the 
development of potential anti-dengue drugs. 
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FIGURE 4. Hydrophobic interactions between compounds 3, 4 and 5, with the binding site. The 2D ligand structures 
are represented as thick purple sticks and the residues of the binding site as brown sticks and and those involved in the 
hydrophobic interactions are depicted with the red eye-lashes. Images were generated using the Ligplot program
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